Cure My Disease

Don't miss your cure!

 Log in / Sign up

A sugar syrup may make colonoscopy prep safer and more effective for diabetics

NCT ID NCT07084350

Disease control Sponsor: General Hospital of Shenyang Military Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether adding lactulose—a type of sugar syrup—to the standard bowel-cleansing drink (PEG-ELS) can improve colonoscopy preparation in people with type 2 diabetes. Diabetic patients often have poor bowel cleansing, which can reduce the quality of the exam. The study will compare the combination against PEG alone in 300 adults, looking at how well the bowel is cleaned and whether side effects like bloating or nausea are reduced.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lactulose added to polyethylene glycol electrolyte solution (PEG-ELS)
What this could lead to
If it works, this could lead to a better-tolerated bowel preparation protocol for people with type 2 diabetes, improving colonoscopy quality.
What could go wrong
This is an early-stage trial with no phase designation, so results may not change practice. Adding lactulose could cause bloating or discomfort in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

Sep 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. age 18\~75 years; 2. patients undergoing colonoscopy; 3. diagnosis of type II diabetes mellitus； 4. sign the informed consent form. Exclusion Criteria: 1. severe heart, lung or liver diseases; 2. bowel resection; 3. intestinal obstruction and massive ascites; 4. women preparing for pregnancy or those who were pregnant and lactating; 5. mental disorders; 6. dysphagia; 7. allergy to any medication used for bowel preparation; 8. have used prokinetic agents (such as domperidone or mosapride) within 14 days prior to the colonoscopy; 9. galactose or fructose intolerance, lactase deficiency, galactosemia, or glucose-galactose malabsorption syndrome.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type II diabetes mellitus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type II diabetes mellitus

Contacts and locations

Locations

  • Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)

    Shenyang, Liaoning, 110840, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.